The fluoropyrimidine antimetabolites 5-fluorouracil (FUra) and 5-fluoro-2'-deoxyuridine (FdUrd) have a prominent role in the treatment of human colorectal tumors as a result of their intrinsic cytotoxic activities as well as their ability to modulate the actions of other therapeutic tools (e.g., radiation and radiosensitizers). In many cases the biological activity of these drugs is due to inhibition of thymidylate synthase (T.S.), although the specific consequences of this inhibition, which ultimately lead to loss of viability, are poorly understood. By using pulsed-field gel electrophoresis we have obtained preliminary data showing that FdUrd-induced cytotoxicity in human colorectal tumor (HCT) cells is associated with the formation of large DNA fragments (up to 5 Mbase), which appear to be the result of non-randomly distributed double strand breaks. Furthermore, we have demonstrated major qualitative and quantitative differences in the fragmentation patterns of different HCT cell lines. We postulate that this damage is a key event in turning DNA synthesis inhibition into an irreversible, lethal insult, and that variations in sensitivity to FdUrd among HCT cell lines may be at least partially due to differences in the processes by which these cells convert T.S. inhibition into double strand breaks. Therefore, the major goal of this project is to understand the mechanism(s) responsible for the formation of DNA double-strand breaks induced by FdUrd, in human colorectal tumor cell lines. We will approach this objective by testing a set of specific hypotheses concerning: -the sequence-specificity of double-strand break formation -the relationship of double strand breaks to single strand break formation -the effect of chromatin conformation on fragment formation

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA056663-03
Application #
2097465
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1993-01-01
Project End
1995-12-31
Budget Start
1995-01-01
Budget End
1995-12-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Pharmacology
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Fridman, J S; Parsels, J; Rehemtulla, A et al. (2001) Cytochrome c depletion upon expression of Bcl-XS. J Biol Chem 276:4205-10
Fridman, J S; Benedict, M A; Maybaum, J (1999) bcl-X(S)-induced cell death in 3T3 cells does not require or induce caspase activation. Cancer Res 59:5999-6004
Rehemtulla, A; Hamilton, A C; Taneja, N et al. (1999) A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation. Neoplasia 1:63-70
Lin, H L; Parsels, L A; Maybaum, J et al. (1999) N-Nitrosodimethylamine-mediated cytotoxicity in a cell line expressing P450 2E1: evidence for apoptotic cell death. Toxicol Appl Pharmacol 157:117-24
Parsels, L A; Parsels, J D; Wagner, L M et al. (1998) Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells. Cancer Chemother Pharmacol 42:357-62
Fridman, J S; Rehemtulla, A; Hofmann, A et al. (1998) Expression of Bcl-XS alters cytokinetics and decreases clonogenic survival in K12 rat colon carcinoma cells. Oncogene 17:2981-91
Parsels, L A; Zellars, R C; Loney, T L et al. (1997) Prevention of fluorodeoxyuridine-induced cytotoxicity and DNA damage in HT29 colon carcinoma cells by conditional expression of wild-type p53 phenotype. Mol Pharmacol 52:600-5
Merchant, A K; Loney, T L; Maybaum, J (1996) Expression of wild-type p53 stimulates an increase in both Bax and Bcl-xL protein content in HT29 cells. Oncogene 13:2631-7
Lawrence, T S; Davis, M A; Tang, H Y et al. (1996) Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression. Int J Radiat Biol 70:273-80
Tang, H Y; Weber, K L; Lawrence, T S et al. (1996) Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells. Cancer Chemother Pharmacol 37:486-90

Showing the most recent 10 out of 15 publications